Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (472)	12/12/2003 10:49:29 AM
From: Arthur Radley	Read Replies (1) of 631

COPENHAGEN, Dec 12 (Reuters) - Danish biotech firm Genmab (Copenhagen:GEN.CO - News) said on Friday it planned to drop the development of a drug for the treatment of psoriasis after tests showed no significant results, sending its shares down as much as 17.7 percent. Genmab said a clinical Phase 2 study of 118 patients did not achieve statistically significant results.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next